US equities |
META $624.47 ▼-0.97% TSLA $401.37 ▲+2.49% MU $922.76 ▲+2.11% NVDA $216.91 ▲+0.42% SPCX $149.54 ▲+1.80% AMD $549.38 ▲+3.41% SNDK $1,292.37 ▲+2.93% INTC $92.35 ▲+2.08%
FinancialContent

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.446 +0.046 (+3.29%)
Delayed Quote Updated: 10:44 AM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
News headline image
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first... 
Via Newsfile
News headline image
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin... 
Via FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Via AB Newswire
Topics Intellectual Property
News headline image
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 ↗
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news 
Via InvestorPlace
News headline image
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
News headline image
3 Cheap Biotech Stocks to Buy Now: May 2024 ↗
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
News headline image
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024 ↗
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
Via AB Newswire
Topics Economy
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Via AB Newswire
News headline image
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Via AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
Via AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
Via AB Newswire
Topics Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Via AB Newswire
Topics Intellectual Property
News headline image
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment ↗
ATNM stock offers moonshot or crash-landing possibilities as Actinium Pharmaceuticals works relentlessly to advance life-changing treatments. 
Via InvestorPlace
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
Via AB Newswire
Topics Intellectual Property
News headline image
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory ↗
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗
 
Via Benzinga
News headline image
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer ↗
Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
< Previous 1 2 3 4 5 Next >